A review of molecular imaging studies reaching the clinical stage

European Journal of Radiology

Volumn 70, Issue 2, 2009, Pages 205-211

  Wong, Franklin C ^a   Kim, E Edmund ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Angiogenesis; Apoptosis; Blood flow; Brain; Cardiomyopathy; Computed tomography (CT); Criteria; Humans; Magnetic resonance imaging (MRI); Magnetic resonance spectroscopy (MRS); Magnetic resonance spectroscopy imaging (MRSI); Metabolism; Movement disorder; Optical imaging perfusion; Positron emission tomography (PET); Receptor; Single photon emission computed tomography (SPECT); Trials; Ultrasound

Indexed keywords

ANGIOGENESIS; APOPTOSIS; BLOOD FLOW; CARDIOMYOPATHY; COMPUTED TOMOGRAPHY (CT); CRITERIA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY IMAGING (MRSI); MOVEMENT DISORDER; OPTICAL IMAGING PERFUSION; RECEPTOR; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT); TRIALS; ULTRASOUND;

ACOUSTIC WAVES; ATOMS; BIOCHEMISTRY; BLOOD; CELL DEATH; COMPUTERIZED TOMOGRAPHY; EMISSION SPECTROSCOPY; HEMODYNAMICS; MAGNETIC MATERIALS; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MAGNETISM; METABOLISM; OPTICAL EMISSION SPECTROSCOPY; OPTICAL IMAGE STORAGE; PARTICLE BEAMS; PARTICLE DETECTORS; PHOTONS; POSITRON ANNIHILATION SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; POSITRONS; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; ULTRASONICS;

ULTRASONIC IMAGING;

CONTRAST MEDIUM; RADIOPHARMACEUTICAL AGENT;

AMINO ACID METABOLISM; ANGIOGENESIS; APOPTOSIS; ARTICLE; BLOOD FLOW; CARBOHYDRATE METABOLISM; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIFFUSION WEIGHTED IMAGING; ECHOGRAPHY; LIPID METABOLISM; MEDICAL TECHNOLOGY; MOLECULAR BIOLOGY; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR MEDICINE; OPTICAL TOMOGRAPHY; PERFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMS BIOLOGY; TISSUE OXYGENATION; X RAY;

CLINICAL MEDICINE; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; GENE EXPRESSION PROFILING; MOLECULAR PROBE TECHNIQUES;

EID: 67349174202     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2009.01.049     Document Type: Article

References (67)

1. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
2. Cai W., Rao J., Gambhir S.S., and Chen X. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther 5 11 (2006) 2624-2633
3. Thoeny H.C., Kessler T.M., Simon-Zoula S., et al. Renal oxygenation changes during acute unilateral ureteral obstruction: assessment with blood oxygen level-dependent mr imaging-initial experience. Radiology 247 3 (2008) 754-761
4. Shen S.H., Chiou Y.Y., Wang J.H., et al. Diffusion-weighted single-shot echo-planar imaging with parallel technique in assessment of endometrial cancer. AJR Am J Roentgenol 190 2 (2008) 481-488
5. Buijs M., Vossen J.A., Hong K., Georgiades C.S., Geschwind J.F., and Kamel I.R. Chemoembolization of hepatic metastases from ocular melanoma: assessment of response with contrast-enhanced and diffusion-weighted MRI. AJR Am J Roentgenol 191 1 (2008) 285-289
6. Mazaheri Y., Shukla-Dave A., Hricak H., et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging-correlation with pathologic findings. Radiology 246 2 (2008) 480-488
7. Manton D.J., Chaturvedi A., Hubbard A., et al. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 94 3 (2006) 427-435
8. Lahaye M.J., Engelen S.M., Kessels A.G., et al. USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria. Radiology 246 3 (2008) 804-811
9. Klibanov A.L. Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Invest Radiol 41 3 (2006) 354-362
10. Mueller A.J., Bartsch D.U., Schaller U., Freeman W.R., and Kampik A. Imaging the microcirculation of untreated and treated human choroidal melanomas. Int Ophthalmol 23 4-6 (2001) 385-393
11. Klerk C.P., Overmeer R.M., Niers T.M., et al. Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. Biotechniques 43 1 Suppl (2007) 7-13 30
12. Mintun M.A., Welch M.J., Siegel B.A., et al. Breast cancer: PET imaging of estrogen receptors. Radiology 169 1 (1988) 45-48
13. Tsujikawa T., Yoshida Y., Mori T., et al. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET-initial experience. Radiology 248 2 (2008) 599-605
14. Hood J.D., and Cheresh D.A. Role of integrins in cell invasion and migration. Nat Rev Cancer 2 2 (2002) 91-100
15. Bach-Gansmo T., Danielsson R., Saracco A., et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med 47 9 (2006) 1434-1439
16. Beer A.J., Grosu A.L., Carlsen J., et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13 22 Pt 1 (2007) 6610-6616
17. Gambhir S.S. Molecualr imaging of cancer: from molecules to humans. J Nucl Med 49 Suppl 2 (2008) 1S-4S [Introduction]
18. Czernin J., and Schelbert H.R. PET/CT in cancer patient management. J Nucl Med 48 Suppl 1 (2007) 2S-3S [Introduction]
19. Gillies R.J., Robey I., and Gatenby R.A. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49 Suppl 2 (2008) 24S-42S
20. Gerson M.C., and McGoron A.J. Technetium 99m glucarate: what will be its clinical role?. J Nucl Cardiol 4 4 (1997) 336-340
21. Yang D., Yukihiro M., Yu D.F., et al. Assessment of therapeutic tumor response using 99mtc-ethylenedicysteine-glucosamine. Cancer Biother Radiopharm 19 4 (2004) 443-456
22. Inoue T., Kim E.E., Wong F.C., et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors. J Nucl Med 37 9 (1996) 1472-1476
23. O'Tuama L.A., Guilarte T.R., Douglass K.H., et al. Assessment of [11C]-l-methionine transport into the human brain. J Cereb Blood Flow Metab 8 3 (1988) 341-345
24. Henze M., Mohammed A., Schlemmer H.P., et al. PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis. J Nucl Med 45 4 (2004) 579-586
25. Inoue T., Koyama K., Oriuchi N., et al. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG-preliminary study. Radiology 220 1 (2001) 54-62
26. Koopmans K.P., Neels O.C., Kema I.P., et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 26 9 (2008) 1489-1495
27. Timmers H.J., Hadi M., Carrasquillo J.A., et al. The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med 48 10 (2007) 1599-1606
28. Heinisch M., Dirisamer A., Loidl W., et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml?. Mol Imaging Biol 8 1 (2006) 43-48
29. Plathow C., and Weber W.A. Tumor cell metabolism imaging. J Nucl Med 49 Suppl 2 (2008) 43S-63S
30. Kurhanewicz J., Vigneron D., Carroll P., and Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol 18 1 (2008) 71-77
31. Laprie A., Catalaa I., Cassol E., et al. Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. Int J Radiat Oncol Biol Phys 70 3 (2008) 773-781
32. Tjuvajev J.G., Macapinlac H.A., Daghighian F., et al. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med 35 9 (1994) 1407-1417
33. Blasberg R.G., Roelcke U., Weinreich R., et al. Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. Cancer Res 60 3 (2000) 624-635
34. van Westreenen H.L., Cobben D.C., Jager P.L., et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med 46 3 (2005) 400-404
35. Troost E.G., Vogel W.V., Merkx M.A., et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 48 5 (2007) 726-735
36. Bading J.R., and Shields A.F. Imaging of cell proliferation: status and prospects. J Nucl Med 49 Suppl 2 (2008) 64S-80S
37. Dimitrakopoulou-Strauss A., and Strauss L.G. The role of 18F-FLT in cancer imaging: does it really reflect proliferation?. Eur J Nucl Med Mol Imaging 35 3 (2008) 523-526 comment
38. Diaz Jr. L.A., Foss C.A., Thornton K., et al. Imaging of musculoskeletal bacterial infections by [124I]FIAU-PET/CT. PLoS ONE 2 10 (2007) e1007
39. Wong D.F., Wagner Jr. H.N., Tune L.E., et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234 4783 (1986) 1558-1563 erratum appears in Science 1987 Feb 6; 235(4789):623
40. Wagner Jr. H.N., Burns H.D., Dannals R.F., et al. Imaging dopamine receptors in the human brain by positron tomography. Science 221 4617 (1983) 1264-1266
41. Wong D.F. Imaging in drug discovery, preclinical, and early clinical development. J Nucl Med 49 6 (2008) 26N-28N
42. Lee C.M., and Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 27 6 (2006) 310-316
43. Gerasimou G.P., Aggelopoulou T.C., Costa D.C., and Gotzamani-Psarrakou A. Molecular imaging (SPECT and PET) in the evaluation of patients with movement disorders. Nucl Med Rev 9 2 (2006) 147-153
44. Eshuis S.A., Maguire R.P., Leenders K.L., Jonkman S., and Jager P.L. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease. Eur J Nucl Med Mole Imaging 33 2 (2006) 200-209
45. Firbank M.J., Burn D.J., McKeith I.G., and O'Brien J.T. Longitudinal study of cerebral blood flow SPECT in Parkinson's disease with dementia, and dementia with Lewy bodies. Int J Geriatr Psychiatry 20 8 (2005) 776-782
46. Bal H., Bal G., and Acton P.D. Diagnosis of Parkinsonian disorders using a channelized Hotelling observer model: proof of principle. Med Phys 34 10 (2007) 3987-3995
47. Tsukamoto T., Morita K., Naya M., et al. Decreased myocardial beta-adrenergic receptor density in relation to increased sympathetic tone in patients with nonischemic cardiomyopathy. J Nucl Med 48 11 (2007) 1777-1782
48. Mankoff D.A., Link J.M., Linden H.M., Sundararajan L., and Krohn K.A. Tumor receptor imaging. J Nucl Med 49 Suppl 2 (2008) 149S-163S
49. Smith-Jones P.M., Solit D., Afroze F., Rosen N., and Larson S.M. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 47 5 (2006) 793-796 see comment
50. Cwikla J.B., Mikolajczak R., Pawlak D., et al. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs. J Nucl Med 49 7 (2008) 1060-1065
51. Li S., and Beheshti M. The radionuclide molecular imaging and therapy of neuroendocrine tumors. Curr Cancer Drug Targets 5 2 (2005) 139-148
52. Krenning E.P., Valkema R., Kwekkeboom D.J., et al. Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. J Nucl Med 46 Suppl 1 (2005) 76S-82S
53. Cai W., and Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 49 Suppl 2 (2008) 113S-128S
54. Kenny L.M., Coombes R.C., Oulie I., et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 49 6 (2008) 879-886
55. Blankenberg F.G. In vivo detection of apoptosis. J Nucl Med 49 Suppl 2 (2008) 81S-95S
56. Alauddin M.M., Shahinian A., Gordon E.M., and Conti P.S. Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model. Mol Imaging 3 2 (2004) 76-84
57. Yaghoubi S., Barrio J.R., Dahlbom M., et al. Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J Nucl Med 42 8 (2001) 1225-1234
58. Radu C.G., Shu C.J., Nair-Gill E., et al. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2′-deoxycytidine analog. Nat Med 14 7 (2008) 783-788
59. Winnard Jr. P.T., Pathak A.P., Dhara S., Cho S.Y., Raman V., and Pomper M.G. Molecular imaging of metastatic potential. J Nucl Med 49 Suppl 2 (2008) 96S-112S
60. Nordberg A. Amyloid plaque imaging in vivo: current achievement and future prospects. Eur J Nucl Med Mol Imaging 35 Suppl 1 (2008) S46-50
61. Drzezga A., Grimmer T., Henriksen G., et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage 39 2 (2008) 619-633
62. Del Vecchio S., Zannetti A., Fonti R., Pace L., and Salvatore M. Nuclear imaging in cancer theranostics. Q J Nucl Med Mol Imaging 51 2 (2007) 152-163
63. Korkmaz M., Kim E.E., Wong F.C., Podoloff D.A., Haynie T.P., and Yung A. In-111 DTPA Ommayagrams in leptomeningeal carcinomatosis. Clin Nucl Med 20 7 (1995) 610-612
64. Anonymous. NIH-FDA Conference: Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications. Disease Markers 14 4 (1998) 187-334 [abstract]
65. Ravina B., Eidelberg D., Ahlskog J.E., et al. The role of radiotracer imaging in Parkinson disease. Neurology 64 2 (2005) 208-215 see comment
66. Nunn A. Imaging biomarkers, an industry perspective. J Nucl Med 49 6 (2008) 28N-32N
67. Conti P.S., McEwan A.J., and Pomper M.G. Molecular imaging: the future of modern medicine. J Nucl Med 49 6 (2008) 16N-20N